vs
Side-by-side financial comparison of KILROY REALTY CORP (KRC) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $158.6M, roughly 1.7× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 6.3%, a 64.9% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -5.0%). KILROY REALTY CORP produced more free cash flow last quarter ($450.3M vs $131.7M).
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
KRC vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $272.2M | $158.6M |
| Net Profit | $17.1M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | — | 70.2% |
| Net Margin | 6.3% | 71.2% |
| Revenue YoY | -5.0% | 3661.1% |
| Net Profit YoY | -73.7% | 528.0% |
| EPS (diluted) | $0.11 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $272.2M | — | ||
| Q3 25 | $279.7M | — | ||
| Q2 25 | $289.9M | — | ||
| Q1 25 | $270.8M | $158.6M | ||
| Q4 24 | $286.4M | $22.6M | ||
| Q3 24 | $289.9M | — | ||
| Q2 24 | $280.7M | — | ||
| Q1 24 | $278.6M | — |
| Q4 25 | $17.1M | — | ||
| Q3 25 | $162.3M | — | ||
| Q2 25 | $79.6M | — | ||
| Q1 25 | $43.7M | $112.9M | ||
| Q4 24 | $65.0M | $-10.5M | ||
| Q3 24 | $57.7M | — | ||
| Q2 24 | $54.5M | — | ||
| Q1 24 | $55.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 6.3% | — | ||
| Q3 25 | 58.0% | — | ||
| Q2 25 | 27.4% | — | ||
| Q1 25 | 16.1% | 71.2% | ||
| Q4 24 | 22.7% | -46.4% | ||
| Q3 24 | 19.9% | — | ||
| Q2 24 | 19.4% | — | ||
| Q1 24 | 20.0% | — |
| Q4 25 | $0.11 | — | ||
| Q3 25 | $1.31 | — | ||
| Q2 25 | $0.57 | — | ||
| Q1 25 | $0.33 | $1.90 | ||
| Q4 24 | $0.50 | $-0.15 | ||
| Q3 24 | $0.44 | — | ||
| Q2 24 | $0.41 | — | ||
| Q1 24 | $0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $179.3M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.4B | $350.1M |
| Total Assets | $10.9B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $179.3M | — | ||
| Q3 25 | $372.4M | — | ||
| Q2 25 | $193.1M | — | ||
| Q1 25 | $146.7M | $274.8M | ||
| Q4 24 | $165.7M | $128.0M | ||
| Q3 24 | $625.4M | — | ||
| Q2 24 | $835.9M | — | ||
| Q1 24 | $855.0M | — |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.5B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | $350.1M | ||
| Q4 24 | $5.4B | $229.0M | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.4B | — | ||
| Q1 24 | $5.4B | — |
| Q4 25 | $10.9B | — | ||
| Q3 25 | $11.0B | — | ||
| Q2 25 | $10.9B | — | ||
| Q1 25 | $10.9B | $406.9M | ||
| Q4 24 | $10.9B | $271.6M | ||
| Q3 24 | $11.4B | — | ||
| Q2 24 | $11.5B | — | ||
| Q1 24 | $11.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $566.3M | $131.8M |
| Free Cash FlowOCF − Capex | $450.3M | $131.7M |
| FCF MarginFCF / Revenue | 165.4% | 83.0% |
| Capex IntensityCapex / Revenue | 42.6% | 0.1% |
| Cash ConversionOCF / Net Profit | 33.10× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $833.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $566.3M | — | ||
| Q3 25 | $176.6M | — | ||
| Q2 25 | $143.7M | — | ||
| Q1 25 | $136.9M | $131.8M | ||
| Q4 24 | $541.1M | $-23.2M | ||
| Q3 24 | $176.3M | — | ||
| Q2 24 | $88.7M | — | ||
| Q1 24 | $167.9M | — |
| Q4 25 | $450.3M | — | ||
| Q3 25 | $148.7M | — | ||
| Q2 25 | $118.4M | — | ||
| Q1 25 | $115.6M | $131.7M | ||
| Q4 24 | $440.8M | $-23.2M | ||
| Q3 24 | $147.2M | — | ||
| Q2 24 | $69.5M | — | ||
| Q1 24 | $151.9M | — |
| Q4 25 | 165.4% | — | ||
| Q3 25 | 53.1% | — | ||
| Q2 25 | 40.9% | — | ||
| Q1 25 | 42.7% | 83.0% | ||
| Q4 24 | 153.9% | -102.7% | ||
| Q3 24 | 50.8% | — | ||
| Q2 24 | 24.7% | — | ||
| Q1 24 | 54.5% | — |
| Q4 25 | 42.6% | — | ||
| Q3 25 | 10.0% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 7.9% | 0.1% | ||
| Q4 24 | 35.0% | 0.2% | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 6.8% | — | ||
| Q1 24 | 5.7% | — |
| Q4 25 | 33.10× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | 3.13× | 1.17× | ||
| Q4 24 | 8.32× | — | ||
| Q3 24 | 3.06× | — | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | 3.01× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
